Your browser is no longer supported. Please, upgrade your browser.
Settings
CNTB [NASD]
Connect Biopharma Holdings Limited
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand57.50M Perf Week2.94%
Market Cap1.31B Forward P/E- EPS next Y-2.34 Insider Trans- Shs Float5.42M Perf Month3.50%
Income- PEG- EPS next Q-1.19 Inst Own28.20% Short Float14.29% Perf Quarter35.26%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio12.41 Perf Half Y-
Book/sh- P/B- EPS next Y-6.40% ROA- Target Price31.04 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.02 - 27.14 Perf YTD23.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.29% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low63.98% ATR1.96
Employees62 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)55.36 Volatility8.47% 9.29%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.20 Prev Close22.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume62.40K Price22.99
Recom1.30 SMA200.03% SMA5016.68% SMA20026.36% Volume4,343 Change1.05%
Apr-13-21Initiated SVB Leerink Outperform $32
Apr-13-21Initiated Piper Sandler Overweight
Apr-13-21Initiated Jefferies Buy $27
Jun-11-21 03:57PM  
May-26-21 08:00AM  
May-25-21 08:00AM  
May-12-21 08:00AM  
Apr-08-21 08:00AM  
Mar-23-21 04:05PM  
Mar-18-21 11:58PM  
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.